Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.

JJ McNeil, AE Anderson, WJ Louis, DJ Morgan

Research output: Contribution to journalArticleResearchpeer-review

38 Citations (Scopus)


1 The pharmacokinetics of labetalol were studied in twelve hypertensive patients, ten of whom were not receiving other therapy. 2 Following intravenous administration there was a three‐ to fourfold variation in terminal elimination half‐life, volume of distribution and total plasma clearance. The mean elimination half‐life was 3.25 hours. 3 Following oral administration the drug was absorbed rapidly. Systemic availability varied from 11‐86% (mean 33%). 4 Plasma levels correlated poorly with the acute effect on BP, raising the possibility of labetalol acting in a deep tissue compartment or alternatively an active metabolite contributing to its effect. 1979 The British Pharmacological Society

Original languageEnglish
Pages (from-to)157S-161S
JournalBritish Journal of Clinical Pharmacology
Issue number2 S
Publication statusPublished - 1 Jan 1979

Cite this